MTOPS Trial: Combination Therapy for BPH Progression Prevention
Medically reviewed by [Reviewer Name, MD, Urology] | Last reviewed: August 2026 | Editorial policy | BPH hub
The Medical Therapy of Prostatic Symptoms (MTOPS) trial (McConnell et al., 2003; N Engl J Med) was a landmark 4–6 year, four-arm RCT that compared finasteride 5 mg, doxazosin (an alpha-1 blocker), the combination of both, and placebo. It established that combination therapy provides significantly superior protection against BPH clinical progression compared to either monotherapy.
Study Design
| Parameter | Details |
|---|---|
| Design | Multicenter, double-blind, randomized, placebo-controlled, 4-arm trial |
| Population | Men with symptomatic BPH (IPSS ≥8); n=3,047 |
| Arms | 1) Placebo; 2) Doxazosin 4–8 mg/day; 3) Finasteride 5 mg/day; 4) Combination |
| Duration | 4–6 years (mean 4.5 years) |
| Primary endpoint | Time to overall clinical progression (rise in IPSS ≥4, AUR, incontinence, renal insufficiency, recurrent UTI) |
Key Results
| Arm | Overall BPH Progression Risk Reduction vs. Placebo |
|---|---|
| Doxazosin monotherapy | 39% |
| Finasteride monotherapy | 34% |
| Combination therapy | 66% |
- Combination was statistically superior to either monotherapy for overall progression
- Finasteride (alone or combined) significantly reduced AUR and surgery risk; doxazosin alone did not
- Combination was not significantly superior to doxazosin alone for preventing AUR specifically
MTOPS fundamentally changed BPH treatment guidelines: combination therapy became standard of care for men with larger prostates (≥40 mL) and elevated PSA at higher risk of progression. See: Finasteride for BPH
Sources
- McConnell JD, et al. “The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.” N Engl J Med. 2003;349(25):2387–2398.